797812-91-0

Usage

Uses

Used in Pharmaceutical Industry:
(2-Isopropyl-benzoimidazol-1-yl)-acetic acid is used as a potential therapeutic agent for the development of anticonvulsant and anti-anxiety medications. Its molecular structure, which includes a benzimidazole ring and an acetic acid group, suggests that it may have properties beneficial in managing conditions related to seizures and anxiety disorders.
Used in Research and Development:
In the field of scientific research, (2-Isopropyl-benzoimidazol-1-yl)-acetic acid serves as a subject of study for its potential therapeutic effects. Researchers are interested in understanding how (2-ISOPROPYL-BENZOIMIDAZOL-1-YL)-ACETIC ACID interacts with biological systems and its possible role in the treatment of various health conditions, pending further investigation and clinical trials.

InChI:InChI=1/C12H14N2O2/c1-8(2)12-13-9-5-3-4-6-10(9)14(12)7-11(15)16/h3-6,8H,7H2,1-2H3,(H,15,16)

Upstream product

• 5851-43-4 2-isopropylbenzimidazole 
• 7748-25-6 potassium chloroacetate 

Relevant academic research and scientific papers

Targeting receptor tyrosine kinase VEGFR-2 in hepatocellular cancer: Rational design, synthesis and biological evaluation of 1,2-disubstituted benzimidazoles

In this study, a novel series of 1,2-disubstituted benzo[d]imidazoles was rationally designed as VEGFR-2 inhibitors targeting hepatocellular carcinoma. Our design strategy is twofold; it aimed first at studying the effect of replacing the 5-methylfuryl moiety of the well-known antiangiogenic 2-furylbenzimidazoles with an isopropyl moiety on the VEGFR-2 inhibitory activity and the cytotoxic activity. Our second objective was to further optimize the structures of the benzimidazole derivatives through elongation of the side chains at their one-position for the design of more potent type II-like VEGFR-2 inhibitors. The designed 1,2-disubstituted benzimidazoles demonstrated potent cytotoxic activity against the HepG2 cell line, reaching IC50 = 1.98 μM in comparison to sorafenib (IC50 = 10.99 μM). In addition, the synthesized compounds revealed promising VEGFR-2 inhibitory activity in the HepG2 cell line, e.g., compounds 17a and 6 showed 82% and 80% inhibition, respectively, in comparison to sorafenib (% inhibition = 92%). Studying the effect of 17a on the HepG2 cell cycle demonstrated that 17a arrested the cell cycle at the G2/M phase and induced a dose-dependent apoptotic effect. Molecular docking studies of the synthesized 1,2-disubstituted benzimidazoles in the VEGFR-2 active site displayed their ability to accomplish the essential hydrogen bonding and hydrophobic interactions for optimum inhibitory activity.

A benzimidazole compound and its preparation method and application

Provided are 2-substituted-N-[5-(2-(N-aryl methylene)amino-1,3,4-thiadiazole)-methylene]-benzimidazole and a preparation method and an application thereof. The preparation method comprises the steps: firstly, with a benzimidazole compound and potassium chloroacetate as raw materials and ethanol as a solvent, carrying out a reflux reaction to obtain a 1-carboxymethyl-benzimidazole compound; then with polyphosphoric acid, the 1-carboxymethyl-benzimidazole compound and thiosemicarbazide as raw materials, carrying out a reflux reaction to obtain 2-substituted-N-[5-(2-amino-1,3,4-thiadiazole)-methylene]-benzimidazole; then with 2-substituted-N-[5-(2-amino-1,3,4-thiadiazole)-methylene]-benzimidazole, aromatic aldehyde and p-toluenesulfonic acid as raw materials, carrying out a solid-phase reaction, and thus obtaining 2-substituted-N-[5-(2-(N-aryl methylene)amino-1,3,4-thiadiazole)-methylene]-benzimidazole. The preparation method has the advantages of simple reaction process, low equipment requirements, simple operation, relatively high target product yield, and small environmental pollution, and the prepared 2-substituted-N-[5-(2-(N-aryl methylene)amino-1,3,4-thiadiazole)-methylene]-benzimidazole can be applied in preparation of drugs inhibiting escherichia coli.